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1. Introduction  
Lymphoproliferative disorders can develop in the setting of many immunosupressive 
conditions, and they have been well established following solid organ transplantation or 
allogeneic bone marrow transplantation (Blaes & Morrison, 2010). The incidence varies, 
depending on the type of organ transplanted, the degree of immunosuppression, the 
number of episodes of acute rejection and the patient's immune status to Epstein-Barr virus. 
The 2008 World Health Organization Classification of Tumours of Haematopoietic and 
Lymphoid Tissues defines monomorphic posttransplant lymphoproliferative disorders 
(PTLD) as lymphoid or plasmacytic proliferations that fulfill the criteria for one of the B-cell 
or T/NK-cell neoplasms recognized in immunocompetent patients. However, indolent B-
cell lymphomas, such as extranodal marginal zone lymphoma of mucosa-associated 
lymphoid tissue (MALT lymphoma), are specifically excluded from this category. 
Autoimmune and chronic inflammatory disorders are also associated with increased risks of 
non-Hodgkin lymphoma (NHL). Concretely in rheumatoid arthritis and systemic lupus 
erythematosus (SLE), an increased risk of malignant lymphomas has been described 
repeatedly, whereas the evidence is less consistent for other inflammatory disorders that 
display autoimmune phenomena, such as psoriasis, inflammatory bowel disorders and 
sarcoidosis. The risk of NHL in SLE patients is estimated to be 3- to 4-fold higher (Smedby et 
al., 2008a). Although the incidence of PTLD is thought to be bimodal and typically related to 
Epstein-Barr virus in the first year after solid-organ transplantation, the relationship 
between Epstein-Barr virus and NHL in SLE and other autoimmune diseases is not yet well 
established. 
Because different NHL subtypes develop at different stages of lymphocyte differentiation, 
the incidence of specific NHL subtypes varies based on the type of autoimmune and 
inflammatory disorder as well as on the type and amount of autoimmune therapy. Data 
regarding the histology of the NHL that develops in patients with SLE suggest that these 
lesions derive from lymphocytes that have been exposed to antigen (Bernatsky et al., 2005a). 
Lymphoma development after the antigen-exposure stages of differentiation might suggest 
that chronic antigenic stimulation has a role in auto immunity-related lymphomas. From the 
lymphoma perspective, diffuse large B-cell lymphomas seem to display the most 
pronounced and general association with autoimmunity and inflammation, although certain 
specific T-cell lymphomas have been linked to distinct autoimmune conditions (e.g. 
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enteropathy-type T-cell lymphoma to coeliac disease) (Smedby et al., 2008b). Studies of 
lymphoproliferative disorders occurring in patients with SLE have shown an increased risk 
of marginal zone lymphoma, predominantly of the MALT type, and of diffuse large B-cell 
lymphoma (DLBCL) (Bernatsky et al., 2005b). 
The mechanisms responsible for the association between lymphoma and SLE remain 
unknown. Exposure to immunosuppressive agents has been blamed for the elevated risk of 
lymphoma, but cases of lymphoma in patients with no history of having received 
immunosuppressive drugs have also been reported. The study of Bernatsky et al looking for 
the incidence of cancer in patients with SLE, reports that the highest relative risk of 
hematological malignancy occurred in the first year after diagnosis of SLE which indicates 
that cancer risk is not completely explained by cumulative doses of immunosuppressive 
drugs (Bernatsky et al., 2005b). 
2. Objective 
SLE is an autoimmune disease characterized by immune mediated attacks against  
the body’s own tissues. The aetiology of the illness is unknown. In essence the 
fundamental rules of tolerance are violated and autorreactive B and T cell clones 
cooperate, proliferate and lead the production of pathogenic auto-antibodies. The 
development of lymphomas and autoimmunity involves an intrincate interplay among 
various pathogenic factors. Besides genetic abnormalities, a variety of environmental and 
microbial factors, as well as abnormal immune-regulatory processes and tolerance 
mechanisms can lead to autoimmunity and the generation of different lymphoma 
subtypes. Within germinal centers, naïve B cells undergo activation, proliferation, somatic 
hypermutation of rearranged V regions genes, isotype switching, and subsequent positive 
and/or negative selection by antigen.  However, the germinal center exclusion of 
autorreaction is defective in SLE and the existence of a defective check point in the 
maintenance of peripheral B cell tolerance appears to be specific to patients with SLE. This 
is important because, some autorreactive B cells may initiate germinal center reactions 
and autorreactivity arises de novo in the germinal center through somatic mutations. 
Moreover, in patients with active SLE a marked B cell lymphopenia that affects naïve  
B cells leads to a relative predominance of memory B cells with multiple somatic 
mutations. Somatic mutations are introduced at a high rate in the germinal center and are 
implicated usually in single nucleotide exchanges. However, deletions and insertions may 
also occur. The involvement of the hypermutation machinery in deletions and insertions 
seem to be the main cause of generation of several lymphoproliferative disorders in  
these patients. 
The aim of the present review is to summarize potential harmful steps in the development 
of lymphocytes, tolerance checkpoints  (anergy, deletion, germinal centre exclusion, receptor 
editing and revision, memory check points, somatic hypermutation) and immune responses 
that induce the acquisition and proliferation of neoplastic lymphocytes in the contex of SLE. 
We also review the different subtypes of lymphoproliferative disorders associated with SLE 
and its management. 
3. Development of B cell repertoire 
B cells are derived from CD34+CD19-CD10+cells. The earliest lineage-committed B cell is 
the pro-B cell, which is characterized by a CD19+ phenotype (Wang et al., 1998). The pro-B 
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cell stage is defined by immunoglobulin (Ig) heavy chain rearrangement initiated via the 
recombinase activating genes RAG1 and RAG2 (Blom & Spits, 2006; LeBien & Tedder, 2008). 
In these cells, DH to JH gene rearrangements occur, often, but not always in both IgH 
alleles, which are located on chromosome 14 in humans (Cobett, et al., 1997; Ravetch, et al., 
1981). In the next, step VH gene segment is rearranged to a DHJH (Cook  & Tomlinson, 
1995). If the first VH/DH/JH rearrangement is nonproductive, the B cell precursor has a 
second chance to generate a productive IgH gene rearrangement by using the second IgH 
allele. When heavy chain gene rearrangement is successful, then Ig class is 
expressed on the cell surface in association with  heavy chain and the signal 
transducing molecules CD79a/b to form the pre-B cell receptor. This is accompanied 
by loss of CD34 and TdT expression and marks the transition to the pre-B-cell stage of 
development. Pre-B cells discontinue further IgH gene rearrangements, divide several times, 
and then initiate light chain gene rearrangements (Rajewsky, 1996). Internalization of the pre-B 
cell receptor and rearrangement of the light chains occur next, defaulting to the kappa gene. 
Lambda gene rearrangement and expression generally occur only if kappa gene 
rearrangement is unsuccessful. Successful light chain rearrangement induces the expression of 
sIgM composed by IgH and either  or  light chains. Failure to rearrange either the heavy or 
light chains induces apoptosis. If immature B cells react with self antigens, mechanisms of 
negative selection can induce apoptosis, receptor edition or anergy (LeBien, 2000).  
Secondary B cell development is characterized by the migration of immature B cells to the 
spleen, where they differentiate into mature naïve B cells, now characterized by surface IgD 
in addition to IgM, CD21 and CD22, as well as a loss of CD10. Positive selection 
subsequently commences, with cells failing to react succumbing to cell death. Following this 
process, mature cells migrate to secondary lymphoid tissue whereupon they can further 
differentiate to plasma cells or establish a germinal center when they recognize an antigen 
(DiLillo, et al., 2008).  
4. Germinal centre reaction 
Within germinal centers, activated B cells undergo the process of somatic hypermutation. 
Centrally proliferating B cells are referred to as centroblasts, which divide to form smaller 
centrocytes that migrate to periphery of the germinal center.  Centroblasts first remove the 
surface immunoglobulin, then undergo several rounds of division and then re-express 
mutated immunoglobulin receptors as centrocytes. Centrocytes expressing BCR with 
increased affinity will be able to appropriately interact with germinal centre T cells and 
follicular dendritic cells and be positively selected. Surviving centrocytes subsequently 
depend on CD40-based interactions with T cells to facilitate differentiation into long lived 
plasma cells and memory B cells (MacLennan, 1994).  
5. Tolerance B cell check points  
B cell precursors undergo immunoglobulin gene rearrangements to generate a population of 
mature B cells bearing surface immunoglobulin (sIg) with a range of specificities. Random 
V/D/J gene assembly generates many self-reactive B-cell receptors (BCR). To avoid 
autoimmunity, B cells displaying self-reactive immunoglobulin are deleted centrally in the 
bone marrow and at subsequent check points in the periphery (Yurasov et al., 2005a) (Fig. 
1). Self reactivity arising during V/D/J recombination could be corrected by receptor 
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editing, clonal deletion and anergy. In normal subjects the number of self reactive B cells 
decreases significantly as B cells progress though normal development. Nevertheless, 
central tolerance appears not enough to control self-reactive B cells in SLE patients. 
Significantly, the frequency of autoreactive antibodies declines from 75% in the bone 
marrow to 20% in the circulating naïve compartment (Yurasov et al., 2005b). However, 
several of these check points appear deficient in SLE patients (Yurasov S, et al., 2005b). In 
patients with SLE, mature naïve B cell compartment comprises 40% to 50% of autoreactive 
clones.  This fact indicates that SLE patients have defects in censoring self reactive B cells 
early in development even in SLE patients in remission (Yurasov et al., 2006). Because 
signaling through the BCR is a primary mechanism for triggering deletion, anergy, or 
receptor edition abnormal BCR signaling is likely to play a role in breakdown tolerance 
(Kamradt & Mitchinson, 2001). Interestingly, circulating mature B cells from SLE patients 
demonstrate a heightened response to BCR crosslinking. Even more SLE patients have low 
levels of intracellular tyrosine kinase Lyn that can diminish BCR signaling through 
phosphorylation of inhibitory receptor such CD22 and FCRIIb (Flores-Borja, et al., 2005). 
 
 
Fig. 1. Defective central tolerance in development of B cell repertoire in SLE. 
Patients with SLE have increased numbers of self-reactive B cells. We speculate that  
defects in complement could contribute to this phenomena. We propose that although 
receptor edition works well in SLE patients if immature B cells cannot test their BCR with 
self-antigens it is possible that they mature to naive self-reactive B cells and leave bone 
marrow and migrate to secondary lymphoid organs.  
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During central tolerance in bone marrow, receptor editing appears to be the preferred 
mechanism to establish early B cell self-tolerance (Tiegs et al., 1993; Gay et al., 1993; Halverson 
et al., 2004). Self reactive BCR can apparently be purged by receptor editing, a mechanism 
through which antigen binding in bone marrow induces continued rearrangement of 
immunoglobulin gene segments; this process results in a change in the specificity of a 
previously autorreactive BCR (Melamed, et al., 1997). Interestingly, although receptor editing 
works well in patients with SLE, it is possible that it could be insufficient to avoid the 
development of self-reactive B cells (Dörner, et al., 1999) and subsequent emigration to lymph 
nodes or spleen. However, the basic question as to whether receptor editing is increased or 
decreased during lupus requires further study (Luning-Prak et al., 2011). Interestingly, 
receptor edition can contribute to generating lymphoproliferative disorders (Chiorazzi, et al., 
2005; Wang, et al., 2008; García-Muñoz et al., 2009; Hatzidimitriou, et al., 2009). 
There are also data showing that regulatory checkpoints exist for B cells in the periphery in 
germinal center and in the late stages of B cell differentiation to memory or long-lived 
plasma cells (Cappione A 3rd et al., 2005; William et al., 2006)  
Germinal center exclusion of self reactive B cells (9G4 B cells) that express self-reactive 
antibodies encoded by the IGVH 4-34 gene is an important peripheral checkpoint to avoid 
interaction of autoreactive B cells with T cells and subsequent generation of 
autoantibodies. For this reason, 9G4 B cells are present only in 5-10% of the naïve B cell in 
healthy donors as well as in the IgM memory compartment and these cells participate in 
less than 1 % of germinal centers of tonsil biopsies.  However, germinal center exclusion is 
defective in SLE patients and evaluation of lymphoid tissue from tonsillar biopsies and 
spleens reveals that the frequency of germinal center 9G4 B cells  in this population is 15% 
to 20% (Cappione A 3rd et al., 2005). The expression of IGHV4-34 heavy chains in 
antibodies is synonymous of autoreactivity against N-acatyllactosamine (NAL) 
determinants expressed by the iI blood group antigen and other self glycoproteins 
including CD45 (Silberstein et al., 1991; Pugh-Bernard et al., 2001. Cappione  AJ, et al., 
2004). Importantly, antibodies against anti-B cell CD45 and a significant fraction of anti-
native double stranded DNA (anti-DNA) use VH4-34 heavy chain and are detected in 
patients with SLE (Pugh-Bernard et al., 2001) and represent about 10-45% of total serum 
IgG in this patients.  However, IGHV4-34 antibodies are virtually undetectable in healthy 
sera because IGHV4-34 cells are censored at multiple check points during B cell 
development to avoid autoimmunity (Pugh-Bernard et al., 2001).  
Preventing the generation of self-reactive memory B cells or long lived plasma cells is 
another important peripheral checkpoint to stay away from autoimmunity. B cells 
expressing self reactive antibodies and broadly bacterially reactive antibodies are 
continuously removed from the repertoire in the transition from naïve to IgM memory B 
cells and selection against self reactive antibodies is implemented before the onset of 
somatic hypermutation (Tsuiji et al., 2006). This checkpoint is supported by data showing a 
decrease in frequency of autoreactive IgM+ memory B cells to 2% from 20% in the mature 
naive B cell population in healthy individuals (Tsuiji et al., 2006). Even when dysfunction of 
this checkpoint in SLE is not yet determined, the fact that memory B cells with IGHV4-34 
have been detected in patients with SLE (Odendhal et al., 2000) provides indirect support 
for some deficiency in this checkpoint.  
The presence of extensive somatic mutations seen in autoantibodies derived from SLE 
patients strongly supports the notion of germinal center maturation of pathogenic, self 
reactive B cells and support defects at several check points. 
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6. Lymphomagenesis in SLE 
Chronic immune stimulation by self antigens and infectious agents together with genetic 
variations of TNF- and IL-10 expression have been suggested to explain 
lymphomagenesis in SLE (Dias et al., 2011; Bertansky et al., 2009). However, the 
mechanism underlying the association between SLE and lymphoma remains unexplained. 
Lymphoproliferative neoplasm could arise from precursor B cells development and in 
pre-germinal center, germinal center or post germinal center differentiation. During 
development and maturation of B cells, they can acquire mutations, deletions or 
translocations that direct the generation of lymphomas. Rearrangements of V/D/J genes, 
receptor editing, somatic hypermutation, and class switching are responsible for DNA 
strand breaks that lead chromosomal aberrations that are in part responsible for 
lymphomagenesis (Küppers et al.,1999). A reasonable hypothesis is that the accumulation 
of clonally expanded self-reactive B cells that recognize self-antigens in the lymph nodes 
may predispose these B cells to DNA breaks, facilitating tumorigenesis (Xu et al., 2001). In 
support of this viewpoint, lymph nodes of patients with SLE have extensive necrosis with 
apoptotic debris (self antigens), with numerous plasma cells within germinal centers. On 
the one hand, these histopathologic features suggest that in lymph nodes it is possible that 
self reactive B cells can suffer somatic hypermutation, class switching and receptor 
edition/revision induced by apoptotic bodies increasing the risk of suffering DNA breaks 
and translocations. On the other hand, B cells with self-reactive specificity are likely to 
present self peptides to autoreactive T cells (Chan et al., 1999). In this context, T cells 
contribute to rescuing and supporting the maturation of self-reactive B cells to plasmatic B 
cells or memory B cells. Significantly, during this process it is possible that some cells 
acquire translocations and DNA alterations that contribute to development of lymphoma. 
In addition, in combination with recognition of self antigens in lymph nodes, self reactive 
B cells also recognize self antigens in bone marrow and acquire translocations or genetic 
alterations during B cell development. Autoreactive B cells may suffer receptor editing 
and V/D/J gene recombination in bone marrow. Recent evidence shows that L chain 
receptor editing occurs not only in bone marrow with a pre-B/immature B cell phenotype 
but also in immature/transitional splenic B cells. Nevertheless, editing at the H chain 
locus appears to occur exclusively in bone marrow cells with pro-B phenotype (Nakajima 
et al., 2009). Receptor editing appears to work well in patients with SLE. However, a 
feature of SLE is an increased production of self-reactive B cells that migrate from bone 
marrow to secondary lymphoid organs. This implies that other mechanisms or defects are 
necessary to maintain central tolerance in bone marrow. Significantly, defects in 
elimination of apoptotic cells and defects in complement components have been proposed 
to explain impaired central tolerance in bone marrow (Carrol, 2004). Interestingly, this 
model suggest that autoantigens from apoptotic cells are presented to immature B cells by 
immune complexes containing C1q, C4b and IgM in bone marrow. In support of this 
model Tripodo, et al., discovered C1q production by bone marrow stromal cells, an 
important part of complement that is involved in clearance of apoptotic cells (Tripodo et 
al., 2007).  
We speculate that the impaired elimination of apoptotic cells in bone marrow and  
lymph nodes could contribute to persistent autoantigenic overstimulation leading to 
refractoriness of autoimmunity and increased risk of chromosomal alterations and 
lymphomas (Fig. 2).  
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7. Hypothetical immunologic mechanisms implicated in generation of 
lymphomas in patients with SLE (Fig 2)  
Deficiency in self-antigen retention induced by defects in complement components or 
impaired clearance of apoptotic B cells will possibly lead to an increased release of self-
reactive B cells from bone marrow to periphery. On the one hand, defects in the complement 
system might produce deficient presentation of antigens in bone marrow and diminish the  
 
 
Fig. 2. Lymphoma development in patients with SLE. 
Impaired clearance of apoptotic cells in concert with insufficiency in germinal centre 
exclusion of self-reactive B cells might induce constant stimulus of these B cells. Naive self-
reactive B cells recognize auto-antigens and become memory B cells and plasma cells that 
produce auto antibodies. Continuous activation of memory B cells raises the risk of 
transformation into DLBC (activated subtype) and marginal zone B cell lymphomas. SLE 
activity and decrease in complement components could contribute to a defect in both  
central tolerance and clearance of apoptotic cells.   
protection of receptor edition mechanism. On the other hand, impaired clearance of 
apoptotic cells in bone marrow induces increased stimulation of immature self-reactive B 
cells that could suffer increased receptor edition in bone marrow or avoid tolerance. 
Importantly, receptor edition also can produce polyreactive B cells or a simple change in 
recognition from an auto-antigen for others that recognize the new edited BCR in an 
immature B cell. These two mechanisms could be implicated in generation of mantle cell 
lymphoma (García-Muñoz et al.,2009) or chronic lymphocytic leukemia with unmutated 
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IGHV genes (Hadzidimitriou et al. 2009). Increased variable region gene recombination and 
heavy or light chain receptor edition in self-reactive B cells of patients with SLE in bone 
marrow could in theory contribute to lymphomagenesis. Self reactive B cells that leave bone 
marrow, enter germinal centres because germinal center exclusion is defective in patients 
with SLE. Within germinal centers, self-reactive B cells recognize self-antigens from 
apoptotic cells and suffer somatic hypermutation, receptor revision, and class switch-
recombination. Some of this self-reactive B cells can be converted into memory B cells or 
plasmatic B cells that produce autoantibodies and return to the sites of antigen stimulation. 
During this process self-reactive B cells can acquire translocations, deletions or mutations 
that make a subtype of lymphoma. Germinal center derived lymphomas are derived by 
transformation from either variable region gene recombination (BCL-2-IgH) in follicular 
lymphoma, somatic hypermutation (BCL-6) in diffuse large B cell lymphoma, or class 
switching in c-myc sporadic Burkitt´s lymphoma (Küppers et al.,1999). (Fig. 3) Post-
germinal center B cell lymphomas are marginal zone lymphoma, small lymphocytic 
lymphoma/chronic lymphocytic leukemia and plasmacytoma and are derived from 
memory B cells and plasma cells (Jaffe ES et al., 2008) (Fig. 3). Interestingly, post-germinal 
center derived lymphomas are commonly associated with antigen stimulation by self-
antigens or infectious agents (Suarez et al., 2006). In a study of 24 patients with malignant 
lymphoma and rheumatic diseases including SLE the majority of diffuse large B cell 
lymphomas exhibited activated phenotype and EBV associated lymphoma comprised only a 
small fraction (Kojima et al., 2006). 
8. Lymphoma and SLE; Therapy 
8.1 Lymphoma subtypes in SLE patients 
Patients with SLE have an increased risk to develop lymphomas specially diffuse large B cell 
lymphoma (Löfstrom et al., 2007; Bernatsky et al., 2005; Bernatsky  et al., 2006: King & 
Costenbader, 2007; Lin et al., 2003; Rossi et al., 2011; Biasiotta et al., 2010; Simon et al., 2007)  
and marginal zone lymphomas (Maeda et al., 2008; Gonzalez et al., 2009; Tektonidou, 2010) 
however, several subtypes have been reported.  
8.2 Highly aggressive B cell lymphomas 
Burkitt lymphoma is a highly aggressive B cell malignancy typically characterized by a 
rapid proliferation rate and the translocation of c-myc [t(8;14), t(8;22) or t(2;8)]. The typical 
immunophenotype of Burkitt lymphoma is sIg+, CD10+,CD19+, CD20+, TdT -, Ki-67+ (90-
100% of cells), bcl-2 -, bcl-6 + (Ferry, 2006) Patients with Burkitt lymphoma often present 
with symptoms of a rapidly enlarging abdominal mass and B symptoms. Bone marrow 
involvement is found in up to 70% of patients, and leptomaningeal spread is common 
(Perkins et al., 2008). Data from patients with SLE and Burkitt lymphoma are scarce, 
however: some case reports or case series include patients with SLE that develop this rare 
malignancy (Posner et al., 1990; Bernatsky et al., 2005). The treatment of Burkitt lymphoma 
is based on intensive chemotherapy. Some highly effective regimens include CODOX-M 
(cyclophosmphamide, vincristine, doxorubicin, high dose methotrexate) alternating with 
IVAC (ifosfamide, etoposide and high-dose cytarabine)(Magrath et al., 1996.) or Hyper-
CVAD (hyper fractioned cyclophosphamie, vincristine, doxorubicin, dexametasona) 
(Thomas et al., 2006) both plus Rituximab. 
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Fig. 3. Origin of Non Hodgkin B cell lymphomas and mechanisms related to their 
development  
During development B cells can acquire translocations, deletions or mutations that make a 
subtype of lymphoma. Pre-germinal center derived lymphomas are CLL unmutated and 
mantle cell lymphoma and some follicular lymphomas. Germinal center derived 
lymphomas are derived by transformation from either variable region gene recombination 
(BCL-2-IgH) in follicular lymphoma, somatic hypermutation (BCL-6)  in diffuse large B cell 
lymphoma, or class switching in c-myc sporadic Burkitt´s lymphoma. Post-germinal center 
B cell lymphomas are marginal zone lymphoma, small lymphocytic lymphoma/chronic 
lymphocytic leukemia and plasmacytoma and are derived from memory B cells and plasma 
cells. 
8.3 CD5+ B cell lymphomas 
CD5+ B cell lymphomas comprises Mantle Cell lymphoma (MCL) and Chronic lymphocytic 
leukemia/Small lymphocytic lymphoma (CLL/SLL). Sometimes patients with SLE develop 
this subtypes of lymphomas (Munzert  et al., 1997; Lugassy et al., 1992). 
8.3.1 Mantle cell lymphoma 
MCL can have a varied initial presentation and clinical course. Most patients are diagnosed 
when they already present an advanced stage disease. Common sites of involvement  
include lymph nodes, spleen, bone marrow gastrointestinal tract and the lymphoid tissue of 
www.intechopen.com
 
Systemic Lupus Erythematosus 
 
392 
Waldeyer´s ring. MCL is characterized by the translocation t(11;14)(q13;q32) which leads to 
the overexpression of cyclin D1. Mutation analysis of the rearranged immunoglobulin´s 
heavy chain variable region (IGHV) genes shows a major subset with unmutated IGHV and 
a smaller  subset displaying mutated IGHV genes (Swerdlow et al., 2008). The treatment of 
MCL is by intensive chemotherapy with R-HyperCVAD (rituximab, cyclophosphamide, 
vincristine, doxorubicin and Dexametasone) alternating with R-MA (Rituximab plus high-
dose methotrexate and cytarabine) (Romaguera et al., 2005) followed by consolidation with 
myeloablative chemotherapy with autologous stem cell transplant in selected patients in 
first complete remission (Dreyling et al., 2005). However, other less intensive treatment 
options include R-CHOP (Howard OM, et al., 2002), Bendamustine (Rummel et al., 2005) 
and Bortezomib (Fisher et al., 2006).  
8.3.2 Chronic lymphocytic leukemia/small lymphocytic lymphoma 
CLL/SLL is an indolent B cell malignancy, which is believed to originate in memory 
antigen-experienced B-cells. Tumors usually involve not only the peripheral blood and 
bone marrow but also lymph nodes, spleen and liver.  The diagnosis of SLL is typically 
applied if the presentations predominantly nodal and the diagnosis of CLL is made when 
the principal involvement is bone marrow and blood. CLL remains an incurable tumor 
and clinical features have very variable presentation, course, and outcome. Risk markers 
and stratification in CLL can be divided in two different entities.  High risk phenotype 
usually expresses unmutated immunoglobulin heavy variable genes (Hamblin et al.,1999) 
CD38 surface marker (Damle et al.,1999), zeta-associated protein 70 (ZAP-70)(Crespo et 
al., 2003) and chromosomal aberrations as 17p (the site of the tumor protein p53) or 11q23 
deletions (the site of the ataxia telangiectasia mutated ATM)(Dörner et al., 2000). Low risk 
phenotype habitually expresses mutated IGVH, lack CD38 and ZAP-70 and has a normal 
karyotype or 13q14 deletion. Additional adverse predictive factors include advanced Rai 
(Rai et al., 1975) and Binet clinical staging (Binet et al., 1981), usage of VH3-21 
independent of VH mutation status (Throsélius et al., 2006) and short lymphocyte 
doubling time (Montserrat et al., 1986). There is no evidence that early treatment of 
asymptomatic patients benefits them. The current advice is that patients who are 
asymptomatic should be managed by watchful waiting until they present symptoms or  
International Workshop on Chronic Lymphocytic Leukemia indications for treatment are 
met (Hallek et al., 1996). First line treatment includes chlorambucil, fludarabine, 
Bendamustine or fludarabine plus cyclophosphamide, either alone or in combination with 
Rituximab (Hallek, 2010) . The choice of therapy is influenced by co-morbidities and 
status performance of patients.   
8.4 Follicular lymphoma 
Coexistence of follicular lymphoma (FL) and SLE has previously been reported (Löftröm et 
al., 2007; Suvajdzic et al., 2011). FL is a neoplasm composed of follicle center (germinal 
center) B cells (typically both centrocytes and centroblast) which usually has at least a partial 
follicular pattern. FL is genetically characterized by the translocation t(14;18)(q32;q21) and 
BCL-2 rearrangements.  
FL involves lymph nodes, spleen, peripheral blood and Waldeyer ring. FL may occasionally 
be primary in extranodal sites. Most patients have widespread disease at diagnosis, 
including peripheral and central (abdominal and thoracic) lymphadenopathy and 
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splenomegaly. Despite widespread disease, patients are usually otherwise asymptomatic 
(Harris et al., 2008). Multiple treatment options exist for patients with newly diagnosed FL, 
ranging from observation only to a variety of combined chemoimmunterapy regimens 
(Bendandi, 2008; Cheson et al., 2011). 
8.5 Diffuse large B-cell lymphomas 
Studies specifically investigating lymphoma and SLE have noted that DLBCL are the most 
common histology when lymphoma occurs in these patients (Gayed et al., 2009). This 
aggressive subtype makes up 30% of lymphomas in the general population, but in SLE 
groups, it accounts for between 38% and 53% of lymphomas (Smedby et al., 2006; Bernatsky 
et al., 2005a). Although DLBCL can occur at any age, it is, in general, a disease of middle-
aged and older adults. Unlike indolent Iymphomas that are almost always widely 
disseminated at diagnosis, DLBCL present as early-stage disease in approximately 30% of 
cases. Clinically, presentation with a rapidly enlarging symptomatic mass is very common, 
with B symptoms (fever, unexplained weight loss > 10% over 6 month interval, or night 
sweats) in one-third of the cases. Extranodal disease in DLBCL can be present in up to 40% 
of cases; common sites include the gastrointestinal tract, bone, and CNS. 
With the application of microarray techniques, three subgroups of DLBCL with distinctive 
gene-expression profiles have been identified on the basis of hierarchical clustering: 
germinal-center B-cell-like, activated B-cell-like, and type 3 DLBCL (Rosenwald et al., 2002). 
A number of recent studies have attempted to define germinal-center and non-germinal 
center phenotypes in DLBCL, using immunohistochemistry markers such as bcl-6, CD10 for 
germinal center and MUM1, IRF4 and CD38 for post-germinal center. In general, a germinal 
center immunophenotype, particularly including Bcl-6 expression, has been associated with 
a better prognosis (Lossos et al., 2004). 
8.5.1 Therapy 
For nearly 20 years anthracycline-based chemotherapy has been the mainstay of treatment, 
because of its proven efficacy, the CHOP (cyclophosphamide/doxorubicin/vincristine/ 
prednisone) regimen being the gold standard of therapy for aggressive NHL. Application of 
this treatment resulted in curing 30% of patients with DLBCL. The standard chemotherapy 
regimen has changed little in the past three decades, but a variety of strategies have been 
tested to identify regimens that might increase the disease-free survival rate for aggressive 
lymphomas. Monoclonal-antibody therapy has been added to the armamentarium and 
represents an advance in therapeutic options. The anti-CD20 monoclonal antibody 
rituximab has been combined with the chemotherapy regimen of CHOP in an attempt to 
improve outcomes; increased remission and survival have been reported with no additional 
toxicity (Friedberg JW & Fisher RI., 2006).  
8.5.2 Limited stages 
Classically, external beam radiation therapy was employed as a single modality in the 
therapy for localized DLBCL, with prolonged disease-free survival of approximately 35%. 
However with the success of anthracycline based chemotherapy in treating advanced 
stage DLBCL, the combination of CHOP with radiotherapy emerged as the strategy of 
choice for treating localized DLBCL (Miller et al., 1998). Several cooperative groups have 
developed clinical assays in order to elucidate which is the best chemotherapy regimen to 
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combine with radiotherapy in these patients. The SWOG group showed advantage for 
progression-free survival (PFS) and overall survival (OS) in patients receiving 3 cycles of 
CHOP followed by involved field radiation (40-50 Gy) versus those who received 8 cycles 
of CHOP alone (Miller et al., 2001). Results worsened with the acquisition risk factors.  
Similar results in advantage for disease-free survival but not for OS were published for 
the ECOG group of patients receiving 8 cycles of CHOP followed by radiotherapy 
consolidation (Horning et al., 2004). The GELA group has also addressed this issue in 
several clinical trials suggesting no advantage for patients receiving radiotherapy and a 
short course of chemotherapy compared to those receiving standard chemotherapy (Reyes 
et al., 2005). Recent reports about the addition of rituximab showed advantages in PFS 
and OS to the historical experience without rituximab therapy (Persky, 2008). Nowadays, 
R-CHOP rather than CHOP would be recommended for these patients. However, no data 
exist to support the use of three courses of R-CHOP chemotherapy with radiation 
consolidation for limited stage disease. In view of the activity of R-CHOP in more 
advanced disease and in spite of the lack of a randomized trial to demonstrate its 
superiority in the setting of three rather than six courses, most clinicians prefer to use R-
CHOP rather than CHOP. 
8.5.3 Advanced stages 
After rituximab was found to have activity in B cell NHL, the GELA group conducted a 
randomized trial to compare CHOP alone vs. R-CHOP in elderly patients (60 to 80 years 
old) with DLBCL. Chemotherapy courses were given every 3 weeks. Patients were 
randomly assigned to receive either eight cycles of CHOP every 21 days or eight cycles of R-
CHOP. They concluded that the addition of rituximab to the CHOP regimen increases the 
complete remission rate and prolongs event-free and OS in this group of patients, without a 
clinically significant increase in toxicity (Coiffier et al., 2002). Once the GELA group proved 
the superiority of R-CHOP-21, Pfreundschuh et al. decided to conduct the trial known as 
MabThera International Trial (MInT) to evaluate CHOP-21, R-CHOP-21, CHOEP-21 and R-
CHOEP-21 in patients aged 18–60 years with favorable prognosis (0-1 adverse risk factors 
according to age-adjusted International Prognostic Index). They concluded that rituximab 
added to six cycles of CHOP is an effective treatment for young patients with good-
prognosis DLBCL (Pfreundschuh et al., 2006). The addition of rituximab to CHOP seems to 
eliminate the advantage of CHOEP over CHOP. This study also proved for the first time 
that rituximab when added to CHOP or CHOEP is effective in patients younger than 60 
with favorable IPI. Following these results, the RICOVER-60 trial was developed to asses 
whether six courses were as effective as eight cycles and whether the addition of rituximab 
to CHOP-14 could improve outcome of patients treated with the CHOP-14 regimen. 
Conclusions of this study were that six cycles of R-CHOP-14 significantly improved event-
free, PFS and OS over six cycles of CHOP-14 treatment. The other major conclusion of this 
study was that six cycles of chemotherapy with or without rituximab was as effective as 
eight cycles (Pfreundschuh et al., 2008). The RICOVER trial has been criticized for not 
including an arm with R-CHOP-21. As CHOP-14 is superior to CHOP-21, and R-CHOP-14 is 
superior to CHOP-14, it is logical to think that R-CHOP-14 should also be superior to R-
CHOP-21. However, many investigators refuse to accept that R-CHOP-14 is the gold 
standard for treatment of DLCL until a randomized study with a control arm of R-CHOP-21 
is carried out (Cabanillas, 2010). 
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8.5.4 Special considerations in DBCL and SLE therapy 
When treatment options for DLBCL in the context of SLE are considered, special caution 
should be taken in order to manage the prognostic factors related to the tumor (e.g. 
histology, genetics and stage) as well as patient-specific factors (e.g. age, comorbidity, and 
general health status), because many lymphoma treatments are gruelling, particularly for 
old or frail individuals (Sehn et al., 2007). Patients with SLE often have both the 
hematopoietic reserve reduced and the immune function altered due to immunossupressive 
drugs thus being therapy-related infections a major problem in these patients. In this 
particular subset of patients with SLE and DLBCL, aggressive surveillance, prophylaxis, and 
treatment of infections are essential to prevent morbidity and mortality. Granulocyte colony 
stimulating factors (G-CSF) are largely used in the treatment of hematologic disorders to 
improve the myelosuppression indirectly induced by the chemotherapy regimen. G-CSF 
reduces the depth and duration of neutropenia in lymphoma patients and thus allows the 
design of more dose intense chemotherapy regimens which were shown to improve 
outcome particularly in patients with DLBCL (Lionne-Huyghe et al., 2006). 
Besides, many SLE patients have deteriorated the glomerular filtration rate and a delay in 
drug excretion, needing the adjust of cytotoxic drugs to creatinine clearance. For this reason, 
management of tumor lysis syndrome in these patients can also be problematic. In order to 
avoid these problems, patients with SLE and renal impairment should be handled following 
chemotherapy schedules with a prephase treatment, in the same way on which are treated 
very aggressive lymphomas and elderly patients (Pfreundschuh, 2004, 2010). Sufficient fluid 
intake must be ensured, and appropriate supportive measures must be provided, including 
frequent electrolyte controls and allopurinol or even rasburicase administration to prevent 
hyperuricemia and tumor lysis syndrome. 
SLE is associated with high cardiovascular morbidity and mortality. Clinically silent 
pulmonary hypertension, right ventricular dysfunction and myocardial perfusion defects 
usually asymptomatic are common in SLE patients (Plazak et al., 2011). A careful evaluation 
by means of echocardiography preferably with tissue doppler study and lung function test 
should be part of the pre-treatment studies to prevent anthracycline toxicity (Buss et al., 
2010). Recommendations for therapy should be similar to elderly DLBCL patients. R-CHOP 
should be administered with close functional monitoring or even excluded if they present 
with cardiac-failure New York Heart Association > 2 and/or an ejection fraction < 50% or 
have a forced expiratory volume in 1 second (FeV1) level < 50% or a diffusion capacity < 
50%. If cardiomyopathy is the only limiting condition, doxorubicin should be replaced by 
liposomal doxorubicin under close monitoring of the cardiac function. (Pfreundschuh, 2010; 
Zaja et al., 2006) 
8.6 Marginal zone lymphoma 
The marginal zone of lymphoid tissues is a unique B-cell compartment that contains B cells 
with a high surface density of IgM and complement receptor 2, and which exhibits a rapid 
activation and immunoglobulin secretion in response to blood-borne T-independent (Weill 
et al., 2009). This micro-anatomic compartment is well developed in lymphoid organs such 
as spleen, mesenteric lymph nodes and mucosa-associated lymphoid tissue or MALT where 
circulation of antigens occurs. Marginal B-cell lymphomas (MZL) are a well categorized 
group of indolent B-cell NHL that arise from the marginal zone of lymphoid tissues. The 
WHO-classification of tumors of hematopoietic and lymphoid tissues distinguish three 
different MZL types: extranodal, splenic and nodal (Isaacson et al., 2008).  
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Despite its common cell origin these three subtypes display differences in their frequency 
and clinical presentation and features according to the organ where the lymphoma arises. 
Extranodal MZL, also known as low-grade B-cell lymphoma of mucosa-associated 
lymphoid tissue (or MALT lymphoma) is the most common MZL subtype accounting for 
approximately 70% of all MZLs (Isaacson et al., 2004, 2008). These subtypes can arise at 
virtually any extranodal site and are commonly associated with chronic antigenic 
stimulation, either as a result of infection (eg, Helicobacter pylori in the stomach) or 
autoimmune disease. Splenic MZL accounts for approximately 20% of all MZLs. (Matutes et 
al., 2008). Patients typically present with an enlarged spleen, involvement of abdominal 
lymph nodes, and bone marrow disease. Liver and leukemic involvement are not 
infrequent.  Nodal MZL is the least common, representing approximately 10% of all MZLs. 
(Arcaini et al., 2009). Patients with nodal MZL, by definition, have lymph node-based 
disease without involvement of the spleen or extranodal sites. 
8.6.1 Therapy 
Therapy of patients with MZL and SLE should not differ from that administered to patients 
without the latter condition. While some patients obtain cure of MALT lymphoma with an 
antibiotic treatment of the infectious causing agent, as occurs in the case of the infections for 
H. pylori, other patients require treatment with radio chemotherapy and immunotherapy 
(Martinelli et al., 2005; Zucca E & Dreyling M., 2008). Approximately 75 % of patients with 
gastric MALT lymphoma achieve a remission following the elimination of H. pylori  
with antibiotics (Du & Isaccson, 2002; Wundisch et al., 2005). The interval of histological 
regression following this treatment is variable, ranging from 1 to 25 months. In the  
cases both of persistent infection or resistant lymphoma, a second attempt with  
the antibiotic therapy is usually recommended (Psyrri et al., 2008). Although antibiotics 
have demonstrated efficacy in early stages of disease, its use is also recommended in 
patients with advanced stages, in those without apparent infection for H. pylori, as in those 
with primary non-gastric disease. However, a therapeutic consensual guide for these 
patients has not yet established, much less for patients with the rare condition of MALT 
lymphoma and SLE. 
In addition, the therapeutic role of treatments against infectious pathogens in non-gastric 
MALT lymphoma is less defined. The therapeutic application of antibiotics against B. 
Bugdorferi in cutaneous MALT lymphoma has been described, as well as the treatment 
against C. psittaci in MALT lymphoma of ocular adnexa  (Bertoni & Zucca, 2005; Ferreri et 
al., 2005). However the association of these pathogens with MALT lymphoma seems to 
show a marked geographical variation and the antibiotic effectiveness of the treatments has 
not been confirmed yet (Husain et al., 2007 ). 
Treatment with the anti-CD20 monoclonal antibody rituximab, chemotherapy and radiation 
therapy as single agents or in combination are alternative therapies for patients failing to 
treatment with antibiotics. Rituximab has demonstrated efficacy in gastric MALT lymphoma 
without H. pylori evidence, in cases of refractory disease, in relapses and in advanced 
disease as well as in localized disease in non-gastric MALT lymphoma (Martinelli et al., 
2005; Thieblemont & Coiffier, 2006). The combined administration of rituximab with 
chemotherapy increases the efficacy of the monoclonal antibody. 
The regimens of chemotherapy include alkylating agents, commonly used in low-grade 
lymphomas, analogues of purines, like the fludarabine, whose use combined with rituximab 
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has proven to be efficacious in patients with gastric and non-gastric MALT lymphoma (Levy et 
al., 2002). Recently, the combination of bendamustine (a new agent combining the alkylating 
and the purine analogue properties) with rituximab has demonstrated a great efficacy in 
achieving remission in MALT lymphoma of any origin with a very successful toxicity profile 
(Kahl et al., 2010). Anthracycline based regimes are occasionally used for young patients with 
aggressive gastric disease and for refractory patients to conventional treatments. 
Splenic MZL is a disease with a relatively indolent course, but the optimal treatment 
strategy and outcome of splenic MZL remains undefined. Patients without a marked 
lymphocytosis, anemia or thrombocytopenia may not require treatment. However there is a 
significant group of patients who die from the lymphoma in a short interval of time (Chacón 
et al., 2002). Before rituximab, the recommended treatment for splenic MZL with 
symptomatic splenomegaly or threatening cytopenia was splenectomy, since chemotherapy 
had limited efficacy. Responses to splenectomy occurred in approximately 90% of patients 
(Sagaert X & Tousseyn T, 2010). Chemotherapy with CHOP and purine analogues such as 
fludarabine or pentostatine demonstrated objective responses (Franco et al., 2003). Presently, 
treatment of such patients with rituximab administered as a single agent or in combination 
has shown remarkable responses with an overall survival comparable to that reported 
following splenectomy (Bennett M & Schechter GP., 2010). Rituximab in combination with 
purine nucleosides may provide further improvement in PFS; however, confirmatory 
prospective trials are necessary. 
As shown, in MZL chronic infections and autoimmune diseases such as SLE induce a 
chronic antigenic stimulation in B lymphocytes, through BCR. This constant stimulation 
induces the molecular NF-κB way, which probably plays a role in the initiation of the 
development of subsequent lymphoma (Thome, 2004; Ngo et al., 2011) Regarding therapy 
we can speculate with the future utility of drugs interacting the NF-κB way such as 
proteosome inhibitors (O'Connor, 2005). 
8.7 Other lymphomas 
Interestingly, a wide variety of lymphomas types with low prevalence has been reported in 
SLE patients. These subtypes include lymphoplasmacytic lymphoma (Papadaki et al., 2003), 
intravascular lymphoma (Sanchez-Cano et al., 2007), Franklin´s disease (García-Muñoz et 
al., 2008.), subcutaneous panniculitis-like T cell lymphoma (Pincus et al., 2009.), ALK-
negative T cell anaplastic large cell lymphoma (Suvajdizc et al.,2003), peripheral T cell 
lymphoma (Löfström et al., 2007) and T cell leukemia/lymphoma (Frisch Stork et al.,2009). 
9. Conclusions 
SLE has an excess of lymphoma unrelated to immunosuppressive therapy. The 
mechanisms underlying the association between SLE and lymphoma remain unknown, 
but it is possible that impaired clearance of apoptotic cells in bone marrow and lymph 
nodes induces amplified stimulation of self-reactive B cells, increasing the risk to DNA 
damage and lymphomagenesis. Patients with SLE have shown an increased risk of 
marginal zone lymphoma, predominantly of the MALT type, and of DLBCL. Treatment of 
lymphoproliferative disorders in SLE does not differ from that administered to patients 
without SLE. Because the outcome is dependent on treatment, patients with SLE and 
suspected lymphoma should be evaluated jointly by both a rheumatologist and a 
hematologist with experience in lymphoproliferative disorders.  
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